Abstract: Compositions and method are therefore disclosed for treating chronic obstructive pulmonary disease (COPD) and/or pulmonary fibrosis (PF). In particular, disclosed a composition that contains one, two, or more cytidine diphosphate (CDP)-conjugated phospholipid precursors selected from the group consisting of CDP-choline, CDP-ethanolamine, and CDP-diacylglycerol in a pharmaceutically acceptable carrier for use in treating COPD and/or PF.
Abstract: The present application is directed to a cochleate composition including one or more cochleates and at least two antifungal compounds selected from amphotericin B, 5-flucytosine, fluconazole, ketoconazole, ravuconazole, albaconazole, itraconazole, posaconazole, isavuconazole and/or voriconazole. Methods of using the antifungal cochleate formulations are also disclosed.
Type:
Grant
Filed:
July 12, 2017
Date of Patent:
September 21, 2021
Assignee:
MATINAS BIOPHARMA NANOTECHNOLOGIES, INC.
Inventors:
Raphael J. Mannino, Ruying Lu, Doug F. Kling
Abstract: The present invention provides a pharmaceutical composition for the lubrication of joints, the pharmaceutical composition comprising a non-ionic tonicity agent comprising a polyol, and liposomes comprising at least one membrane comprising at least one phospholipid (PL) selected from a glycerophospholipid (GPL), said GPL having two C12-C18 hydrocarbon chains, being the same or different, and sphingomyelin (SM) having a C12-C18 hydrocarbon chain, the pharmaceutical composition being essentially free of an additional pharmaceutically active agent, wherein the at least one membrane has a phase transition temperature in the range of about 20° C. to about 39° C. and the joint has a joint temperature which is above the phase transition temperature.
Abstract: A liposomal drug formulation for treating a disease in a patient characterized by overexpression of HIF-1? and/or HIF-2? includes a plurality of liposomes in a pharmaceutically acceptable carrier. The liposomes encapsulate echinomycin and are made from a peglyated phospholipid, a neutral phosphoglyceride, and a sterol. The PEGylated liposomes may be used to treat proliferative diseases, leukemia, cancer, autoimmune diseases and graft-versus-host disease.
Type:
Grant
Filed:
November 9, 2016
Date of Patent:
September 14, 2021
Assignee:
CHILDRENS RESEARCH INSTITUTE, CHILDRENS NATIONAL MEDICAL CENTER
Inventors:
Yang Liu, Yin Wang, Yan Liu, Christopher Bailey, Pan Zheng
Abstract: A method for providing a sterile pharmaceutical composition in a pre-filled syringe, the method including solubilizing an active agent and a pH adjusting agent in a solvent to provide a pharmaceutical composition, filtering the pharmaceutical composition through a membrane to provide a sterile pharmaceutical composition, and providing the sterile pharmaceutical composition in a pre-filled syringe having a labeled size, wherein the active agent includes sugammadex, the pre-filled syringe has a headspace volume that is less than 7.5% of the labeled size, and the method is free of a heat-based sterilization process. Also provided are sterile pharmaceutical compositions prepared according to the method.
Abstract: Disclosed herein are glucose-sensitive drug delivery systems including polymeric shell encapsulating an active agent. Upon exposure to a sufficient concentration of glucose, the shell is ruptured, releasing the active agent for absorption.
Abstract: Provided are liposome constructs for delivery of urea to the vitreoretinal interface of the eye. The liposome constructs are agglomerates of small lamellar vesicles (SUVs) and have a greater density than the vitreal fluid, such that they sink to the back of the eye rather than dispersing throughout the vitreous.
Abstract: Embodiments of the present disclosure are related to multivesicular liposome formulations encapsulating zinc meloxicam complex microparticles. Methods of making the zinc meloxicam complex microparticles and administering the zinc meloxicam complex microparticles encapsulated in multivesicular liposome formulations and their use as medicaments are also provided.
Type:
Grant
Filed:
July 2, 2020
Date of Patent:
June 22, 2021
Assignee:
Pacira Pharmaceuticals, Inc.
Inventors:
Louie Daniel Garcia, Stephanie Kurz, Soroush Ardekani, Kathleen Dunne Albright Los, Katherine Stone, Ernest G. Schutt, Vladimir Kharitonov
Abstract: Described herein is a method for loading a hydrophilic compound into liposomes after addition of an alkylester group to form an esterified compound. After loading, the alkylester is hydrolyzed to reform the hydrophilic compound inside the liposomes. Also described is a method for loading drugs under a glucuronide methylester form into liposomes. The glucuronide methylester form of the drug is saponified to a glucuronide form of the drug inside the liposomes for better drug retention. The glucuronide residue conjugated to drugs can be removed inside cells to regenerate the parental drug upon cell uptake, liposomal degradation and enzyme hydrolysis. In case of cancer, this method can be used to safely deliver drugs to tumors.
Abstract: To provide a preparing method for a charged niosome which is formed of a lipid containing a diacylglycerol PEG adduct and which is capable of being excellently impregnated into the skin and stored in the skin.
Type:
Grant
Filed:
July 20, 2018
Date of Patent:
May 11, 2021
Assignee:
J-NETWORK, INC.
Inventors:
Tatsuro Miyoshi, Brian Charles Keller, Akira Kodama
Abstract: Inhalable pharmaceutical compositions can include an aqueous dispersion of particles including a hydrophobic bioactive agent (e.g., CoQ10) suitable for continuous aerosolization. Due to their chemical composition and methods of manufacture, the pharmaceutical compositions exhibit distinctive physicochemical properties that provide advantageous aerosol transmission and output.
Type:
Grant
Filed:
June 18, 2012
Date of Patent:
April 13, 2021
Assignee:
Berg LLC
Inventors:
Niven Rajin Narain, John Patrick McCook
Abstract: Disclosed herein is an ocular drug delivery system, comprising a positively charged chitosan-modified hydrogel, a secretory phospholipase A2 (sPLA2) hydrolysable liposome encapsulating an anti-inflammatory drug and having a negative surface charge, a first thiolated hyaluronic acid (HA-SH) nanoparticle encapsulating a wound-healing drug and having a negative surface charge, and a second HA-SH nanoparticle encapsulating a transforming growth factor-? inhibitor and having a negative surface charge. The sPLA2 hydrolysable liposome and the first and second HA-SH nanoparticles are attached to the positively charged chitosan-modified hydrogel by electrostatic attraction. Uses of the system are also disclosed.
Abstract: A tetravalent platinum compound-bicyclic double-bond-containing amphiphilic polymer prodrug, which has the structure as shown in formula (I): when m=1, represents when m=0, represents R represents —CH3 or —CH2CH3; L1 and L2 independently represent Cl, N3, NO3, and n is from 10 to 80. A preparation method of the prodrug is also disclosed. The method includes a step of reacting an axially dihydroxy-coordinated tetravalent platinum compound with a bicyclic double-bond-containing orthoester precursor. In addition, a nano-micelle formed by the prodrug and an application thereof are further disclosed. The amphiphilic polymer prodrug and the micelle formed therefrom have pH hypersensitivity and reduction dual responsiveness.
Abstract: Provided are serum-stable nanoparticles comprising porphyrin-phospholipid conjugates. Also provided are compositions comprising the nano-particles. The nanoparticles can comprise cargo such as therapeutic agents and/or diagnostic agents (e.g., imaging agents) and be used in drug delivery methods based on NIR stimulated cargo release.
Type:
Grant
Filed:
April 4, 2016
Date of Patent:
February 16, 2021
Assignee:
The Research Foundation for The State University of New York
Inventors:
Jonathan Lovell, Dandan Luo, Kevin Carter, Shuai Shao, Jumin Geng
Abstract: Systems and methods for producing liposomes, including control liposomes and immunoliposomes targeting breast cancer are provided. Systems and methods for treating breast cancer, using targeted immunoliposomes produced according to various methods are also disclosed herein. For example, trastuzumab-conjugated immunoliposomes may be used to deliver chemotherapeutic agents to breast cancer tissues for the treatment of breast cancer. Systems and methods for actuating liposomes using ultrasound are also disclosed, such as systems and methods for actuating trastuzumab-conjugated liposomes accumulated in breast cancer tissues for the treatment of breast cancer.
Type:
Grant
Filed:
October 12, 2018
Date of Patent:
December 15, 2020
Assignee:
American University of Sharjah
Inventors:
Ghaleb Husseini, Mohammad Al-Sayah, Amal Elsadig
Abstract: The invention provides a new method for preparing ultra-small polymeric-lipidic delivery nanoparticles (USDNs) that were synthesized by a nanoprecipitation method followed by a layer-by-layer nanodeposition. The USDNs particle size can be controlled between 5-25 nm and provides loading capacities of 22.12% to 72.08%. Moreover, the USDNs platform provides pH controlled drug release, within a terminal release ratio of 68% at pH 5.0 and almost no release to pH of 7.5. Furthermore, based on their small sizes (5-25 nm) and unique composition, the USDNs penetrates the skin strata efficiently, release the payload at the target site as topical or transdermal treatment of a variety of skin disorders. Additionally the USDNs system can be used to treat and diagnoses other crucial diseases (Cancer, Alzheimer, etc) can be combined with various micro-needles or needles free array technologies for special application.
Abstract: The present disclosure provides a composition of matter comprising liposomes encapsulating in their intraliposomal aqueous compartment at least one active agent, the liposomes having a diameter of at least 200 nm and being embedded in a water insoluble, water absorbed cross-linked polymeric matrix. In one embodiment, the composition of matter is held within an aqueous medium, preferably being in iso-osmotic equilibrium with the intraliposomal aqueous compartments of the liposomes.
Type:
Grant
Filed:
January 22, 2019
Date of Patent:
November 24, 2020
Assignee:
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
Abstract: Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed. These formulations display superior drug retention profiles and also maintain size distribution following lyophilization and reconstitution.
Type:
Grant
Filed:
November 5, 2018
Date of Patent:
November 17, 2020
Assignee:
CELATOR PHARMACEUTICALS, INC.
Inventors:
Donna Cabral-Lilly, Lawrence Mayer, Paul Tardi, David Watkins, Yi Zeng